Crispr Therapeutics (NASDAQ:CRSP) issued its earnings results on Monday. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.84), Briefing.com reports. The company had revenue of $0.32 million during the quarter, compared to analyst estimates of $47.57 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The business’s revenue was down 70.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.82) earnings per share.

CRSP opened at $50.66 on Tuesday. The firm has a market capitalization of $2.75 billion, a PE ratio of -14.73 and a beta of 3.11. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $59.00. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average price is $47.31.

CRSP has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price (down previously from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. Chardan Capital set a $73.00 target price on Crispr Therapeutics and gave the stock a “buy” rating in a research report on Friday, June 7th. Zacks Investment Research cut EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Barclays set a €38.00 ($44.19) target price on Dialog Semiconductor and gave the stock a “buy” rating in a research report on Tuesday. Finally, Roth Capital initiated coverage on Crispr Therapeutics in a research report on Monday, June 10th. They issued a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and an average price target of $55.90.

In related news, President Rodger Novak sold 50,000 shares of Crispr Therapeutics stock in a transaction on Monday, June 10th. The stock was sold at an average price of $45.00, for a total transaction of $2,250,000.00. Following the completion of the sale, the president now owns 898,007 shares of the company’s stock, valued at $40,410,315. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lawrence Otto Klein sold 20,000 shares of Crispr Therapeutics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $50.02, for a total value of $1,000,400.00. Following the sale, the insider now directly owns 31,579 shares of the company’s stock, valued at approximately $1,579,581.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,000 shares of company stock valued at $6,670,400. Insiders own 21.40% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Do investors pay a separate front-end load every time they buy additional shares?

Earnings History for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.